Investigation of ABL Kinase Inhibitory Potential of Bioactive From Juglans Regia: Molecular Docking, Pharmacophore Modelling and Molecular Dynamics Simulation Study
Sep 2026· International Journal of Applied Pharmaceutics· 0 citations
TL;DR
Investigation of phytoconstituents of Juglans regia derived from IMPPAT database as inhibitors of the Abelson tyrosine kinase, identifies plumbagin as a candidate for c-Abl kinase inhibitor.
Abstract
Objective: The present study aimed to investigate the potential of phytoconstituents of Juglans regia derived from IMPPAT database as inhibitors of the Abelson tyrosine kinase (c-Abl), using in silico tools.
Methods: Physicochemical and pharmacokinetic properties were predicted using QikProp, while toxicity profiles were evaluated with admetSAR. The molecular docking was performed against c-Abl kinase (PDB ID: 2HYY), followed by MM-GBSA binding free energy calculations. Pharmacophore modelling identified key interaction features, and 100 ns molecular dynamics (MD) simulations assessed complex stability. Prediction of Activity Spectra for Substances (PASS) prediction was used to predict potential biological activities.
Results: Most phytoconstituents exhibit favourable drug-likeness and oral bioavailability with acceptable pharmacokinetic and low predicted toxicity. Molecular docking analysis identified plumbagin as the potential compound among phytoconstituents, exhibiting a docking score of −10.27 kcal/mol. Plumbagin showed predicted interactions including hydrogen bonding, hydrophobic interactions, and π–π stacking. Binding free energy calculations further supported the stability of the complex. Pharmacophore modelling highlighted the hydroxyl group and aromatic naphthoquinone scaffold as key features responsible for ligand binding. Molecular dynamics (MD) simulations demonstrated the ligand exhibited positional deviations within the binding pocket, indicating dynamic binding behaviour. PASS prediction predicted that plumbagin may possess neuroprotective effects, including antioxidant, anti-inflammatory, and cytoprotective effects.
Conclusion: The findings identify plumbagin as a candidate for c-Abl kinase inhibitor. However, further in vitro and in vivo studies are required to validate its efficacy and safety.
INTRODUCTION/OBJECTIVE
Janus kinase 1 (JAK1) is a key controller and regulator of cytokinemediated immune responses and an effective therapeutic target in autoimmune and inflammatory diseases. In the present study, an in silico workflow was implemented to identify secondary metabolites of mushrooms as prospective JAK1-...
Bushra Shakoor, Ali Irfan, M. Muhammed et al.· Current Medicinal Chemistry· 0 citations
Findings show that kaempferol is a viable lead compound for cholera toxin suppression and serve as the foundation for future antitoxin medication development and experimental validation.
H. M. Zohaib, Madiha Saqlain, I. Tabassum et al.· Computational biology and ch...· 0 citations
INTRODUCTION/OBJECTIVE
The KRAS G12D mutation is a significant oncogenic factor that promotes cell proliferation and tumor development, particularly in pancreatic cancer. Inhibiting the mutated form of the KRAS protein is a critical strategy in cancer treatment. While molecules like MRTX1133 show promise, the limited e...
Ebru Okutan, Serra Özışık, V. Atalay· Current pharmaceutical desig...· 0 citations
Overall, vitexin shows promising binding characteristics as a natural compound targeting Mpro, but it does not surpass the native ligand in terms of overall binding stability, warranting further optimization and experimental validation.
Syahida Djasang, Artati Artati· Journal of the Turkish Chemi...· 0 citations
The present study suggests that lupeol exhibits favorable binding interaction with AURKA and suitable pharmacokinetic properties, supporting its potential as a lead compound for further in vitro and in vivo anti hepatocellular cancer evaluation.
Nuhu Mohammed, U. Abdullahi, Ahmadu Saleh et al.· UMYU Scientifica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.